KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Astrana Health (ASTH) Loans and Notes Receivables (2019 - 2025)

Astrana Health (ASTH) has disclosed Loans and Notes Receivables for 6 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Loans and Notes Receivables changed N/A to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $4.9 million for FY2025, N/A changed from the prior year.
  • Loans and Notes Receivables hit $4.9 million in Q4 2025 for Astrana Health, down from $5.9 million in the prior quarter.
  • In the past five years, Loans and Notes Receivables ranged from a high of $5.9 million in Q3 2025 to a low of $516000.0 in Q4 2022.
  • Historically, Loans and Notes Receivables has averaged $3.2 million across 4 years, with a median of $4.0 million in 2021.
  • Biggest five-year swings in Loans and Notes Receivables: tumbled 37.74% in 2021 and later plummeted 87.1% in 2022.
  • Year by year, Loans and Notes Receivables stood at $4.0 million in 2021, then tumbled by 87.1% to $516000.0 in 2022, then surged by 88.57% to $973000.0 in 2023, then surged by 406.27% to $4.9 million in 2025.
  • Business Quant data shows Loans and Notes Receivables for ASTH at $4.9 million in Q4 2025, $5.9 million in Q3 2025, and $973000.0 in Q3 2023.